GlaxoSmithKline is nearing a deal to acquire Stiefel Laboratories, a US maker of skin care pharmaceuticals, for about $3bn. A deal between UK-based GlaxoSmithKline and privately-held Stiefel, controlled by the Stiefel family and part-owned by buyout group Blackstone, could be announced as early as Monday, although the two companies were still discussing terms of an agreement on Sunday.

This entry was posted by Gwen Robinson on Monday, April 20th, 2009 at 4:55 and is filed under Capital markets, M&A. Tagged with Stiefel. Edit this entry.